|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tian T, Song C, Jiang L, Dai J, Lin Y, Xu
X, Yu C, Ge Z, Ding Y, Wen Y, et al: Hepatitis B virus infection
and the risk of cancer among the Chinese population. Int J Cancer.
147:3075–3084. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vogel A, Meyer T, Sapisochin G, Salem R
and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu Y, Pan J, Gao F, Xu W, Li H and Qi X:
Efficacy and Safety of PD-1/PD-L1 inhibitors in advanced
hepatocellular carcinoma: A systematic review and meta-analysis.
Adv Ther. 40:521–549. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu J, Zhang J, Wang Y, Shu G, Lou C and
Du Z: HAIC vs. TACE for patients with unresectable hepatocellular
carcinoma: A systematic review and meta-analysis. Medicine
(Baltimore). 101:e323902022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin CC, Yang TS, Yen CJ, Cheng R, Liu J
and Hsu C: Safety and preliminary efficacy of ramucirumab in
combination with FOLFOX4 in patients with advanced hepatocellular
carcinoma: A nonrandomized, open-label, phase Ib study. Oncologist.
25:e1921–e1929. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang Z, Tong Y, Yang L, He X, Bao G and Du
X: Identifying optimal therapies in patients with advanced
hepatocellular carcinoma: A systematic review and network
meta-analysis. Transl Gastroenterol Hepatol. 7:382022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
European Association for the Study of the
Liver. Electronic address, . simpleeasloffice@easloffice.eu:
Corrigendum to ‘EASL clinical practice guidelines: Management of
hepatocellular carcinoma’ [J Hepatol 69 (2018) 182–236]. J Hepatol.
70:8172019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Benson AB, D'Angelica MI, Abbott DE,
Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang
DT, et al: Guidelines Insights: Hepatobiliary cancers, version
2.2019. J Natl Compr Canc Netw. 17:302–310. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Omata M, Cheng AL, Kokudo N, Kudo M, Lee
JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al:
Asia-Pacific clinical practice guidelines on the management of
hepatocellular carcinoma: A 2017 update. Hepatol Int. 11:317–370.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kokudo N, Takemura N, Hasegawa K, Takayama
T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, et al:
Clinical practice guidelines for hepatocellular carcinoma: The
Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019
update. Hepatol Res. 49:1109–1113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu H, Qin X, Jiang H, Sun C, Wu M, Xu Z,
Lu T, Ma X and Han Z: Comparison of hepatic arterial infusion
chemotherapy and transarterial chemoembolization for advanced
hepatocellular carcinoma: A systematic review and meta-analysis. J
Gastrointestin Liver Dis. 31:336–343. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kong S, Yu H, Wang H, Song J and Yan J:
Hepatic arterial infusion chemotherapy combined with sorafenib vs.
sorafenib alone for advanced hepatocellular carcinoma: A systematic
review and meta-analysis. Clin J Gastroenterol. Sep 23–2023.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li
Q, Lu Y, Chen Y, Guo Y, et al: Sintilimab plus a bevacizumab
biosimilar (IBI305) vs. sorafenib in unresectable hepatocellular
carcinoma (ORIENT-32): A randomised, open-label, phase 2–3 study.
Lancet Oncol. 22:977–990. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Q, You N, Li J, Wu K, Peng X, Wang Z,
Wang L, Zhu Y and Zheng L: Camrelizumab plus sorafenib vs.
sorafenib monotherapy for advanced hepatocellular carcinoma: A
retrospective analysis. Front Oncol. 11:6944092021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mei J, Tang YH, Wei W, Shi M, Zheng L, Li
SH and Guo RP: Hepatic arterial infusion chemotherapy combined with
PD-1 inhibitors plus lenvatinib vs. PD-1 inhibitors plus lenvatinib
for advanced hepatocellular carcinoma. Front Oncol. 11:6182062021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qin S: Camrelizumab combined with apatinib
for first-line treatment of unresectable or metastatic
hepatocellular carcinoma: Total population and Chinese subgroup
results. 2022.CSCO Annual Meeting 2 oral report. Available:.
http://meeting.csco.org.cn/Resource/
|
|
19
|
Chen X, Li W, Wu X, Zhao F, Wang D, Wu H,
Gu Y, Li X, Qian X, Hu J, et al: Safety and efficacy of sintilimab
and anlotinib as first line treatment for advanced hepatocellular
carcinoma (KEEP-G04): A single-arm phase 2 study. Front Oncol.
12:9090352022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Tulder M, Furlan A, Bombardier C and
Bouter L; Editorial Board of the Cochrane Collaboration Back Review
Group, : Updated method guidelines for systematic reviews in the
cochrane collaboration back review group. Spine (Phila Pa 1976).
28:1290–1299. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin
WP, Zheng L, Chen MS, Shi M, Wei W and Guo RP: Anti-PD-1
immunotherapy improves the efficacy of hepatic artery infusion
chemotherapy in advanced hepatocellular carcinoma. J Hepatocell
Carcinoma. 8:167–176. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Y, Zheng S, Zhang Z, Chen G, Chen X,
Zheng T, Guo X, Chen H, Wang M, Xie X and Zhang B: Hepatic arterial
infusion chemotherapy with oxaliplatin plus raltitrexed as an
alternative option in advanced hepatocellular carcinoma patients
with failure of, or unsuitability for, transarterial
chemoembolization. Medicina (Kaunas). 58:13432022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li
SL, Deng HJ, He M, Mu LW and Zhao M: Arterial chemotherapy of
oxaliplatin plus fluorouracil vs. sorafenib in advanced
hepatocellular carcinoma: A biomolecular exploratory, Randomized,
phase III trial (FOHAIC-1). J Clin Oncol. 40:468–480. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li QJ, He MK, Chen HW, Fang WQ, Zhou YM,
Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, et al: Hepatic arterial
infusion of oxaliplatin, fluorouracil, and leucovorin vs.
transarterial chemoembolization for large hepatocellular carcinoma:
A Randomized phase III trial. J Clin Oncol. 40:150–160. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xin Y, Cao F, Yang H, Zhang X, Chen Y, Cao
X, Zhou X, Li X and Zhou J: Efficacy and safety of atezolizumab
plus bevacizumab combined with hepatic arterial infusion
chemotherapy for advanced hepatocellular carcinoma. Front Immunol.
13:9291412022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu Y, Fu S, Mao Y, Huang S, Li D and Wu J:
Efficacy and safety of hepatic arterial infusion chemotherapy
combined with programmed cell death protein-1 antibody and
lenvatinib for advanced hepatocellular carcinoma. Front Med
(Lausanne). 9:9190692022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo L, Xiao Y, Zhu G, Huang A, Song S,
Wang T, Ge X, Xie J, Deng W, Hu Z, et al: Hepatic arterial infusion
chemotherapy combined with PD-1 inhibitors and tyrosine kinase
inhibitors for unresectable hepatocellular carcinoma: A tertiary
medical center experience. Front Oncol. 12:10046522022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D,
Li Q, Xu L, Zhang Y, Wei W, et al: Lenvatinib, toripalimab plus
hepatic arterial infusion chemotherapy in patients with high-risk
advanced hepatocellular carcinoma: A biomolecular exploratory,
phase II trial. Eur J Cancer. 174:68–77. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu
SX, Zhang X, Wang XD, Cao G, Chen H, et al: Real-world study of
hepatic artery infusion chemotherapy combined with anti-PD-1
immunotherapy and tyrosine kinase inhibitors for advanced
hepatocellular carcinoma. Immunotherapy. 13:1395–1405. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kokudo N, Hasegawa K, Akahane M, Igaki H,
Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, et al:
Evidence-based Clinical Practice Guidelines for Hepatocellular
Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC
Guidelines). Hepatol Res. 45:2015. View Article : Google Scholar
|
|
31
|
Long F, Chen S, Li R, Lin Y, Han J, Guo J,
Chen Y, Li C and Song P: Efficacy and safety of HAIC alone vs. HAIC
combined with lenvatinib for treatment of advanced hepatocellular
carcinoma. Med Oncol. 40:1472023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang W, Ouyang D, Huang Z and Che X:
Hepatic arterial infusion chemotherapy vs. sorafenib for advanced
hepatocellular carcinoma with portal vein tumor thrombus: An
updated meta-analysis and systematic review. Front Oncol.
13:10851662023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zheng K, Zhu X, Fu S, Cao G, Li WQ, Xu L,
Chen H, Wu D, Yang R, Wang K, et al: Sorafenib plus hepatic
arterial infusion chemotherapy vs. sorafenib for hepatocellular
carcinoma with major portal vein tumor thrombosis: A Randomized
trial. Radiology. 303:455–464. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Llovet JM, Villanueva A, Marrero JA,
Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M,
Mandrekar SJ, et al: Trial design and endpoints in hepatocellular
carcinoma: AASLD consensus conference. Hepatology. 73 (Suppl
1):S158–S191. 2021. View Article : Google Scholar
|
|
35
|
Wang ZX, Wu HX, Xie L, Lin WH, Liang F, Li
J, Yang ZM and Xu RH: Exploration of modified progression-free
survival as a novel surrogate endpoint for overall survival in
immuno-oncology trials. J Immunother Cancer. 9:e0021142021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Llovet JM, Montal R and Villanueva A:
Randomized trials and endpoints in advanced HCC: Role of PFS as a
surrogate of survival. J Hepatol. 70:1262–1277. 2019. View Article : Google Scholar : PubMed/NCBI
|
